Wegovy, Zepbound Prices Drop, But Most Patients Still Can’t Afford Long-Term Use: ‘Coverage Is Not The Same As Access,’ Says Expert

All NewsJuly 7, 2025

Popular obesity treatments Wegovy and Zepbound are seeing price reductions, but patients still face significant barriers to sustained access.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent